Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Proteasome inhibition targets the KMT2A transcriptional complex in acute lymphoblastic leukemia

13 Feb 2023

Abstract excerpt

Rearrangments in Histone-lysine-N-methyltransferase 2A (KMT2Ar) are associated with pediatric, adult and therapy-induced acute leukemias. Infants with KMT2Ar acute lymphoblastic leukemia (ALL) have a poor prognosis with an event-free-survival of 38%. Herein we evaluate 1116 FDA approved compounds in primary KMT2Ar infant ALL specimens and identify a sensitivity to proteasome inhibition. Upon exposure to this...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Lymphoblastic Leukemia research
Share to Acute Myeloid Leukemia Research
Share to Epigenetics and DNA Methylation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36781850
DOI: 10.1038/s41467-023-36370-x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Proteasome inhibition targets the KMT2A transcriptional complex in acute lymphoblastic leukemiaPMID 36781850Read ↗

Updates in KMT2A Gene Rearrangement in Pediatric Acute Lymphoblastic LeukemiaSemantic proximity Read ↗

KMT2A Rearrangements in Leukemias: Molecular Aspects and Therapeutic PerspectivesSemantic proximity Read ↗

Epigenetic changes in human model KMT2A leukemias highlight early events during leukemogenesis.Semantic proximity Read ↗

KMT2A rearranged acute lymphoblastic leukaemia: Unravelling the genomic complexity and heterogeneity of this high-risk disease.Semantic proximity Read ↗

Insights into KMT2A rearrangements in acute myeloid leukemia: from molecular characteristics to targeted therapiesSemantic proximity Read ↗

Acute Myeloid Leukemias with Alterations of Lysine Methyltransferase 2A (KMT2A): Recent Therapeutic DevelopmentsSemantic proximity Read ↗

Updates in the biology and therapy for infant acute lymphoblastic leukemiaSemantic proximity Read ↗

Targeting the Menin-KMT2A Axis in Acute Leukemia: From Epigenetic Dependency to Clinical Translation.Semantic proximity Read ↗

Single-cell transcriptomics reveals a distinct developmental state of KMT2A-rearranged infant B-cell acute lymphoblastic leukemia.Semantic proximity Read ↗

Multi-omics analysis defines highly refractory RAS burdened immature subgroup of infant acute lymphoblastic leukemiaSemantic proximity Read ↗

SET-PP2A complex as a new therapeutic target in KMT2A (MLL) rearranged AML.Semantic proximity Read ↗

Revumenib for patients with acute leukemia: a new tool for differentiation therapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.